Alternative splicing programs in prostate cancer

International Journal of Cell Biology

Volumn , Issue , 2013, Pages

  Sette, Claudio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; CYCLIN D1; EMETINE; EPIDERMAL GROWTH FACTOR RECEPTOR; KRUPPEL LIKE FACTOR 6; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL X; PROTEIN BCL XL; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR ERG;

ABLATION THERAPY; ALTERNATIVE RNA SPLICING; APOPTOSIS; CANCER PROGNOSIS; CELL PROLIFERATION; CELL VIABILITY; DNA DAMAGE; ENHANCER REGION; EXON; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; INTRON; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVIEW; RNA PROCESSING; RNA SEQUENCE; SIGNAL TRANSDUCTION; STOP CODON; TRANSCRIPTION INITIATION;

EID: 84883187664     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2013/458727     Document Type: Review

References (76)

1. Feldman B. J., Feldman D., The development of androgen-independent prostate cancer. Nature Reviews Cancer 2001 1 1 34 45 2-s2.0-0035496220
2. Kohli M., Tindall D. J., New developments in the medical management of prostate cancer. Mayo Clinic Proceedings 2010 85 1 77 86 2-s2.0-73649094457 10.4065/mcp.2009.0442
3. Knudsen K. E., Scher H. I., Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clinical Cancer Research 2009 15 15 4792 4798 2-s2.0-68049140791 10.1158/1078-0432.CCR-08-2660
4. Dehm S. M., Tindall D. J., Alternatively spliced androgen receptor variants. Endocrine-Related Cancer 2011 18 5 R183 R196 2-s2.0-80054931284 10.1530/ERC-11-0141
5. Kalsotra A., Cooper T. A., Functional consequences of developmentally regulated alternative splicing. Nature Reviews Genetics 2011 12 10 715 729 2-s2.0-80053027909 10.1038/nrg3052
6. Zhang C., Li H.-R., Fan J.-B., Wang-Rodriguez J., Downs T., Fu X.-D., Zhang M. Q., Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics 2006 7 article 202 2-s2.0-33646364024 10.1186/1471-2105-7-202
7. David C. J., Manley J. L., Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes and Development 2010 24 21 2343 2364 2-s2.0-78049416081 10.1101/gad.1973010
8. Pal S., Gupta R., Davuluri R. V., Alternative transcription and alternative splicing in cancer. Pharmacology & Therapeutics 2012 136 3 283 294
9. Li Y., Alsagabi M., Fan D., Bova G. S., Tewfik A. H., Dehm S. M., Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Research 2011 71 6 2108 2117 2-s2.0-79952772097 10.1158/0008-5472.CAN-10-1998
10. Dehm S. M., Schmidt L. J., Heemers H. V., Vessella R. L., Tindall D. J., Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 2008 68 13 5469 5477 2-s2.0-48549089747 10.1158/0008-5472.CAN-08-0594
11. Hu R., Dunn T. A., Wei S., Isharwal S., Veltri R. W., Humphreys E., Han M., Partin A. W., Vessella R. L., Isaacs W. B., Bova G. S., Luo J., Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 2009 69 1 16 22 2-s2.0-58249110391 10.1158/0008-5472.CAN-08-2764
12. Guo Z., Yang X., Sun F., Jiang R., Linn D. E., Chen H., Chen H., Kong X., Melamed J., Tepper C. G., Kung H.-J., Brodie A. M. H., Edwards J., Qiu Y., A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 2009 69 6 2305 2313 2-s2.0-65549168746 10.1158/0008-5472.CAN-08-3795
13. Li Y., Chan S. C., Brand L. J., Hwang T. H., Silverstein K. A., Dehm S. M., Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Research 2013 73 2 483 489
14. Narla G., Heath K. E., Reeves H. L., Li D., Giono L. E., Kimmelman A. C., Glucksman M. J., Narla J., Eng F. J., Chan A. M., Ferrari A. C., Martignetti J. A., Friedman S. L., KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001 294 5551 2563 2566 2-s2.0-18244389734 10.1126/science. 1066326
15. Liu X., Gomez-Pinillos A., Loder C., Carrillo-de Santa Pau E., Qiao R., Unger P. D., Kurek R., Oddoux C., Melamed J., Gallagher R. E., Mandeli J., Ferrari A. C., KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. The American Journal of Pathology 2012 181 3 1007 1016
16. Narla G., DiFeo A., Reeves H. L., Schaid D. J., Hirshfeld J., Hod E., Katz A., Isaacs W. B., Hebbring S., Komiya A., McDonnell S. K., Wiley K. E., Jacobsen S. J., Isaacs S. D., Walsh P. C., Zheng S. L., Chang B.-L., Friedrichsen D. M., Stanford J. L., Ostrander E. A., Chinnaiyan A. M., Rubin M. A., Xu J., Thibodeau S. N., Friedman S. L., Martignetti J. A., A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Research 2005 65 4 1213 1222 2-s2.0-13944252065 10.1158/0008-5472.CAN-04-4249
17. Narla G., DiFeo A., Fernandez Y., Dhanasekaran S., Huang F., Sangodkar J., Hod E., Leake D., Friedman S. L., Hall S. J., Chinnaiyan A. M., Gerald W. L., Rubin M. A., Martignetti J. A., KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. Journal of Clinical Investigation 2008 118 8 2711 2721 2-s2.0-48749088691 10.1172/JCI34780
18. Narla G., Difeo A., Yao S., Banno A., Hod E., Reeves H. L., Qiao R. F., Camacho-Vanegas O., Levine A., Kirschenbaum A., Chan A. M., Friedman S. L., Martignetti J. A., Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Research 2005 65 13 5761 5768 2-s2.0-21344473196 10.1158/0008-5472.CAN-05-0217
19. Knudsen K. E., The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Division 2006 1 article 15 2-s2.0-33845394286 10.1186/1747-1028-1- 15
20. Knudsen K. E., Diehl J. A., Haiman C. A., Knudsen E. S., Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006 25 11 1620 1628 2-s2.0-33645118564 10.1038/sj.onc.1209371
21. Lu F., Gladden A. B., Diehl J. A., An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Research 2003 63 21 7056 7061 2-s2.0-0242526150
22. Comstock C. E. S., Augello M. A., Pe Benito R., Karch J., Tran T. H., Utama F. E., Tindall E. A., Wang Y., Burd C. J., Groh E. M., Hoang H. N., Giles G. G., Severi G., Hayes V. M., Henderson B. E., Le Marchand L., Kolonel L. N., Haiman C. A., Baffa R., Gomella L. G., Knudsen E. S., Rui H., Henshall S. M., Sutherland R. L., Knudsen K. E., Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clinical Cancer Research 2009 15 17 5338 5349 2-s2.0-65049089363 10.1158/1078-0432.CCR-08-2865
23. Augello M. A., Burd C. J., Birbe R., McNair C., Ertel A., Magee M. S., Frigo D. E., Wilder-Romans K., Shilkrut M., Han S., Jernigan D. L., Dean J. L., Fatatis A., McDonnell D. P., Visakorpi T., Feng F. Y., Knudsen K. E., Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. The Journal of Clinical Investigation 2013 123 1 493 508
24. Olshavsky N. A., Comstock C. E. S., Schiewer M. J., Augello M. A., Hyslop T., Sette C., Zhang J., Parysek L. M., Knudsen K. E., Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Research 2010 70 10 3975 3984 2-s2.0-77952796886 10.1158/0008-5472.CAN-09-3468
25. Paronetto M. P., Cappellari M., Busà R., Pedrotti S., Vitali R., Comstock C., Hyslop T., Knudsen K. E., Sette C., Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Research 2010 70 1 229 239 2-s2.0-75149187424 10.1158/0008-5472.CAN-09-2788
26. Kaida D., Berg M. G., Younis I., Kasim M., Singh L. N., Wan L., Dreyfuss G., U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation. Nature 2010 468 7324 664 668 2-s2.0-78649847070 10.1038/nature09479
27. Bielli P., Busà R., Paronetto M. P., Sette C., The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocrine-Related Cancer 2011 18 4 R91 R102 2-s2.0-80051951015 10.1530/ERC-11-0041
28. Boise L. H., Gonzalez-Garcia M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., Nunez G., Thompson C. B., bcl-x, A bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993 74 4 597 608 2-s2.0-0027282044 10.1016/0092-8674(93)90508-N
29. Mercatante D. R., Bortner C. D., Cidlowski J. A., Kole R., Modification of alternative splicing of Bcl-x Pre-mRNA in prostate and breast cancer cells: analysis of apoptosis and cell death. Journal of Biological Chemistry 2001 276 19 16411 16417 2-s2.0-0035844238 10.1074/jbc.M009256200
30. Mercatante D. R., Mohler J. L., Kole R., Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. Journal of Biological Chemistry 2002 277 51 49374 49382 2-s2.0-0345829926 10.1074/jbc.M209236200
31. Bauman J. A., Li S.-D., Yang A., Huang L., Kole R., Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Research 2010 38 22 8348 8356 2-s2.0-78650440393 10.1093/nar/gkq731
32. Chalfant C. E., Rathman K., Pinkerman R. L., Wood R. E., Obeid L. M., Ogretmen B., Hannun Y. A., De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. Journal of Biological Chemistry 2002 277 15 12587 12595 2-s2.0-0037066727 10.1074/jbc.M112010200
33. Boon-Unge K., Yu Q., Zou T., Zhou A., Govitrapong P., Zhou J., Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism. Chemistry and Biology 2007 14 12 1386 1392 2-s2.0-37149011077 10.1016/j.chembiol.2007.11.004
34. Kim M. H., Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen. Journal of Cellular Biochemistry 2008 104 4 1491 1499 2-s2.0-46949097093 10.1002/jcb.21725
35. Novoyatleva T., Heinrich B., Tang Y., Benderska N., Butchbach M. E. R., Lorson C. L., Lorson M. A., Ben-Dov C., Fehlbaum P., Bracco L., Burghes A. H. M., Bollen M., Stamm S., Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Human Molecular Genetics 2008 17 1 52 70 2-s2.0-37549002103 10.1093/hmg/ddm284
36. Ghosh N., Patel N., Jiang K., Watson J. E., Cheng J., Chalfant C. E., Cooper D. R., Ceramide-activated protein phosphatase involvement in insulin resistance via Akt, serine/arginine-rich protein 40, and ribonucleic acid splicing in L6 skeletal muscle cells. Endocrinology 2007 148 3 1359 1366 2-s2.0-33847036385 10.1210/en.2006-0750
37. Garneau D., Revil T., Fisette J.-F., Chabot B., Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. Journal of Biological Chemistry 2005 280 24 22641 22650 2-s2.0-20744450092 10.1074/jbc.M501070200
38. Paronetto M. P., Achsel T., Massiello A., Chalfant C. E., Sette C., The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. Journal of Cell Biology 2007 176 7 929 939 2-s2.0-33947712084 10.1083/jcb.200701005
39. Zhou A., Ou A. C., Cho A., Benz E. J. Jr., Huang S.-C., Novel splicing factor RBM25 modulates Bcl-x Pre-mRNA 5′ splice site selection. Molecular and Cellular Biology 2008 28 19 5924 5936 2-s2.0-52649127884 10.1128/MCB.00560-08
40. Pedrotti S., Busà R., Compagnucci C., Sette C., The RNA recognition motif protein RBM11 is a novel tissue-specific splicing regulator. Nucleic Acids Research 2012 40 3 1021 1032 2-s2.0-84856945928 10.1093/nar/gkr819
41. Revil T., Pelletier J., Toutant J., Cloutier A., Chabot B., Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform. Journal of Biological Chemistry 2009 284 32 21458 21467 2-s2.0-69249087295 10.1074/jbc.M109.019711
42. Moore M. J., Wang Q., Kennedy C. J., Silver P. A., An alternative splicing network links cell-cycle control to apoptosis. Cell 2010 142 4 625 636 2-s2.0-77955662560 10.1016/j.cell.2010.07.019
43. Cloutier P., Toutant J., Shkreta L., Goekjian S., Revil T., Chabot B., Antagonistic effects of the SRp30c protein and cryptic 5′ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. Journal of Biological Chemistry 2008 283 31 21315 21324 2-s2.0-52049094582 10.1074/jbc.M800353200
44. ' splice site selection of Bcl-x pre-mRNA. The FASEB Journal 2006 20 10 1680 1682 2-s2.0-33749349897 10.1096/fj.05-5021fje
45. Busà R., Paronetto M. P., Farini D., Pierantozzi E., Botti F., Angelini D. F., Attisani F., Vespasiani G., Sette C., The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 2007 26 30 4372 4382 2-s2.0-34347348168 10.1038/sj.onc.1210224
46. Sette C., Post-translational regulation of star proteins and effects on their biological functions. Advances in Experimental Medicine and Biology 2010 693 54 66 2-s2.0-79952199620 10.1007/978-1-4419-7005-3-4
47. Brignatz C., Paronetto M. P., Opi S., Cappellari M., Audebert S., Feuillet V., Bismuth G., Roche S., Arold S. T., Sette C., Collette Y., Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Molecular and Cellular Biology 2009 29 24 6438 6448 2-s2.0-71949096690 10.1128/MCB.00398-09
48. Paronetto M. P., Farini D., Sammarco I., Maturo G., Vespasiani G., Geremia R., Rossi P., Sette C., Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. American Journal of Pathology 2004 164 4 1243 1251 2-s2.0-1642292426
49. Hu Y., Dobi A., Sreenath T., Cook C., Tadase A. Y., Ravindranath L., Cullen J., Furusato B., Chen Y., Thangapazham R. L., Mohamed A., Sun C., Sesterhenn I. A., McLeod D. G., Petrovics G., Srivastava S., Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clinical Cancer Research 2008 14 15 4719 4725 2-s2.0-51049118579 10.1158/1078-0432.CCR-08-0531
50. Wang J., Cai Y., Yu W., Ren C., Spencer D. M., Ittmann M., Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Research 2008 68 20 8516 8524 2-s2.0-54249154706 10.1158/0008-5472.CAN-08-1147
51. Zammarchi F., Boutsalis G., Cartegni L., 5′ UTR control of native ERG and of Tmprss2: ERG variants activity in prostate cancer. PLoS One 2013 8 3 e49721
52. Muñoz M. J., Santangelo M. S. P., Paronetto M. P., de la Mata M., Pelisch F., Boireau S., Glover-Cutter K., Ben-Dov C., Blaustein M., Lozano J. J., Bird G., Bentley D., Bertrand E., Kornblihtt A. R., DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 2009 137 4 708 720 2-s2.0-65549147264 10.1016/j.cell.2009.03.010
53. Rajan P., Dalgliesh C., Carling P. J., Buist T., Zhang C., Grellscheid S. N., Armstrong K., Stockley J., Simillion C., Gaughan L., Kalna G., Zhang M. Q., Robson C. N., Leung H. Y., Elliott D. J., Identification of novel androgen-regulated pathways and mrna isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS One 2011 6 12 2-s2.0-83355176377 10.1371/journal.pone.0029088 e29088
54. Morgan T. M., Koreckij T. D., Corey E., Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Current Cancer Drug Targets 2009 9 2 237 249 2-s2.0-62549100016 10.2174/156800909787580999
55. Sun J., Blair A. L., Aiyar S. E., Li R., Cofactor of BRCA1 modulates androgen-dependent transcription and alternative splicing. Journal of Steroid Biochemistry and Molecular Biology 2007 107 3-5 131 139 2-s2.0-34548482266 10.1016/j.jsbmb.2007.05.031
56. Clark E. L., Coulson A., Dalgliesh C., Rajan P., Nicol S. M., Fleming S., Heer R., Gaughan L., Leung H. Y., Elliott D. J., Fuller-Pace F. V., Robson C. N., The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Research 2008 68 19 7938 7946 2-s2.0-54249167990 10.1158/0008-5472.CAN-08-0932
57. Zonta E., Bittencourt D., Samaan S., Germann S., Dutertre M., Auboeuf D., The RNA helicase DDX5/p68 is a key factor promoting c-fos expression at different levels from transcription to mRNA export. Nucleic Acids Research 2013 41 1 554 564
58. Hönig A., Auboeuf D., Parker M. M., O'Malley B. W., Berget S. M., Regulation of alternative splicing by the ATP-dependent DEAD-box RNA helicase p72. Molecular and Cellular Biology 2002 22 16 5698 5707 2-s2.0-0036318541 10.1128/MCB.22.16.5698-5707.2002
59. Dong X., Sweet J., Challis J. R. G., Brown T., Lye S. J., Transcriptional activity of androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Molecular and Cellular Biology 2007 27 13 4863 4875 2-s2.0-34347332370 10.1128/MCB.02144-06
60. Rajan P., Gaughan L., Dalgliesh C., El-Sherif A., Robson C. N., Leung H. Y., Elliott D. J., The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. Journal of Pathology 2008 215 1 67 77 2-s2.0-42949156643 10.1002/path.2324
61. Karni R., De Stanchina E., Lowe S. W., Sinha R., Mu D., Krainer A. R., The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nature Structural and Molecular Biology 2007 14 3 185 193 2-s2.0-33847630730 10.1038/nsmb1209
62. Anczuków O., Rosenberg A. Z., Akerman M., Das S., Zhan L., Karni R., Muthuswamy S. K., Krainer A. R., The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nature Structural and Molecular Biology 2012 19 2 220 228 2-s2.0-84856759933 10.1038/nsmb.2207
63. Adesso L., Calabretta S., Barbagallo F., Capurso G., Pilozzi E., Geremia R., Delle Fave G., Sette C., Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 2013 32 2848 2857 10.1038/onc.2012.306
64. Bianchini A., Loiarro M., Bielli P., Busà R., Paronetto M. P., Loreni F., Geremia R., Sette C., Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 2008 29 12 2279 2288 2-s2.0-57349100323 10.1093/carcin/bgn221
65. Furic L., Rong L., Larsson O., Koumakpayi I. H., Yoshida K., Brueschke A., Petroulakis E., Robichaud N., Pollak M., Gabouryd L. A., Pandolfi P. P., Saad F., Sonenberg N., EIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences of the United States of America 2010 107 32 14134 14139 2-s2.0-77956275419 10.1073/pnas.1005320107
66. Naro C., Sette C., Phosphorylation-mediated regulation of alternative splicing in cancer. International Journal of Cell Biology. In press
67. Zhou Z., Qiu J., Liu W., Zhou Y., Plocinik R. M., Li H., Hu Q., Ghosh G., Adams J. A., Rosenfeld M. G., Fu X. D., The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Molecular Cell 2012 47 3 422 433
68. Matter N., Herrlich P., König H., Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002 420 6916 691 695 2-s2.0-0037069651 10.1038/nature01153
69. Al-Ayoubi A. M., Zheng H., Liu Y., Bai T., Eblen S. T., Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion. Molecular and Cellular Biology 2012 32 14 2880 2893
70. Shalek A. K., Satija R., Adiconis X., Gertner R. S., Gaublomme J. T., Raychowdhury R., Schwartz S., Yosef N., Malboeuf C., Lu D., Trombetta J. J., Gennert D., Gnirke A., Goren A., Hacohen N., Levin J. Z., Park H., Regev A., Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 2013 10.1038/nature12172
71. Pedrotti S., Bielli P., Paronetto M. P., Ciccosanti F., Fimia G. M., Stamm S., Manley J. L., Sette C., The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. EMBO Journal 2010 29 7 1235 1247 2-s2.0-77950524790 10.1038/emboj.2010.19
72. Meyer N. H., Tripsianes K., Vincendeau M., Madl T., Kateb F., Brack-Werner R., Sattler M., Structural basis for homodimerization of the Src-associated during mitosis, 68-kDa protein (Sam68) Qua1 domain. Journal of Biological Chemistry 2010 285 37 28893 28901 2-s2.0-77956542688 10.1074/jbc.M110.126185
73. Bonnal S., Vigevani L., Valcárcel J., The spliceosome as a target of novel antitumour drugs. Nature Reviews Drug Discovery 2012 11 11 847 859
74. Pedrotti S., Sette C., Spinal muscular atrophy: a new player joins the battle for SMN2 exon 7 splicing. Cell Cycle 2010 9 19 3874 3879 2-s2.0-77958485605 10.4161/cc.9.19.13153
75. Hua Y., Sahashi K., Rigo F., Hung G., Horev G., Bennett C. F., Krainer A. R., Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011 478 7367 123 126 2-s2.0-80053902729 10.1038/nature10485
76. Zammarchi F., De Stanchina E., Bournazou E., Supakorndej T., Martires K., Riedel E., Corben A. D., Bromberg J. F., Cartegni L., Antitumorigenic potential of STAT3 alternative splicing modulation. Proceedings of the National Academy of Sciences of the United States of America 2011 108 43 17779 17784 2-s2.0-80055072546 10.1073/pnas.1108482108